Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS-04 in Hematologic Malignancies
NCT06820268Phase 1Recruiting
- Sponsor
- Fosun Pharma
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XS-04 in hematologic malignancy, B cell lymphoma, acute myeloid leukemia (AML) and 1 more, sponsored by Fosun Pharma. Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose and/or Recommended Phase II Dose up to 24 months. Started Jan 2025; status: recruiting.
02
Drugs
XS-04
03
Conditions
hematologic malignancyB cell lymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06820268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820268.